PURPOSE: To retrospectively analyze treatment outcomes after particle therapy using protons or carbon ions for mucosal melanoma of the head and neck (HNMM) at the Hyogo Ion Beam Medical Center, as well as to compare proton therapy (PT) and carbon ion therapy (CIT). PATIENTS AND METHODS: Data from 62 HNMM patients without metastasis, treated with PT or CIT between October 2003 and April 2011 were analyzed. Median patient age was 70.5 years (range 33-89 years). Of the total patients, 33 (53 %) had received PT and 29 (47 %) had undergone CIT. Protocols for 65 or 70.2 GyE in 26 fractions were used for both ion types. RESULTS: Median follow-up was 18.0 months (range 5.2-82.7 months). The 1-/2-year overall survival (OS) and local control (LC) rates were 93 %/61 % and 93 %/78 % for all patients, 91 %/44 % and 92 %/71 % for the PT patients and 96 %/62 % and 95 %/59 % for the CIT patients, respectively. No significant differences were observed between PT and CIT. Local recurrence was observed in 8 patients (PT: 5, CIT: 3) and 29 (PT: 18, CIT: 11) experienced distant metastases. Acute reactions were acceptable and all patients completed the planned radiotherapy. Regarding late toxicity, grade 3 or greater events were observed in 5 patients (PT: 3, CIT: 2), but no significant difference was observed between PT and CIT. CONCLUSION: Our single-institution retrospective analysis demonstrated that particle therapy for HNMM achieved good LC, but OS was unsatisfactory. There were no significant differences between PT and CIT in terms of either efficacy or toxicity.
PURPOSE: To retrospectively analyze treatment outcomes after particle therapy using protons or carbon ions for mucosal melanoma of the head and neck (HNMM) at the Hyogo Ion Beam Medical Center, as well as to compare proton therapy (PT) and carbon ion therapy (CIT). PATIENTS AND METHODS: Data from 62 HNMM patients without metastasis, treated with PT or CIT between October 2003 and April 2011 were analyzed. Median patient age was 70.5 years (range 33-89 years). Of the total patients, 33 (53 %) had received PT and 29 (47 %) had undergone CIT. Protocols for 65 or 70.2 GyE in 26 fractions were used for both ion types. RESULTS: Median follow-up was 18.0 months (range 5.2-82.7 months). The 1-/2-year overall survival (OS) and local control (LC) rates were 93 %/61 % and 93 %/78 % for all patients, 91 %/44 % and 92 %/71 % for the PT patients and 96 %/62 % and 95 %/59 % for the CIT patients, respectively. No significant differences were observed between PT and CIT. Local recurrence was observed in 8 patients (PT: 5, CIT: 3) and 29 (PT: 18, CIT: 11) experienced distant metastases. Acute reactions were acceptable and all patients completed the planned radiotherapy. Regarding late toxicity, grade 3 or greater events were observed in 5 patients (PT: 3, CIT: 2), but no significant difference was observed between PT and CIT. CONCLUSION: Our single-institution retrospective analysis demonstrated that particle therapy for HNMM achieved good LC, but OS was unsatisfactory. There were no significant differences between PT and CIT in terms of either efficacy or toxicity.
Authors: Mauricio A Moreno; Dianna B Roberts; Michael E Kupferman; Franco DeMonte; Adel K El-Naggar; Michelle Williams; David S Rosenthal; Ehab Y Hanna Journal: Cancer Date: 2010-05-01 Impact factor: 6.860
Authors: Stephanie E Combs; Stephan Konkel; Christoph Thilmann; Jürgen Debus; Daniela Schulz-Ertner Journal: Strahlenther Onkol Date: 2007-02 Impact factor: 3.621
Authors: M Mizumoto; H Hashii; M Senarita; S Sakai; T Wada; T Okumura; K Tsuboi; H Sakurai Journal: Strahlenther Onkol Date: 2013-02-28 Impact factor: 3.621
Authors: Daniela Schulz-Ertner; Anna Nikoghosyan; Christoph Thilmann; Thomas Haberer; Oliver Jäkel; Christian Karger; Michael Scholz; Gerhard Kraft; Michael Wannenmacher; Jürgen Debus Journal: Strahlenther Onkol Date: 2003-09 Impact factor: 3.621
Authors: David G Pfister; Sharon Spencer; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; A Dimitrios Colevas; Frank Dunphy; David W Eisele; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Bruce H Haughey; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Merrill S Kies; William M Lydiatt; Ellie Maghami; Thomas McCaffrey; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; Cristina P Rodriguez; Sandeep Samant; Jatin P Shah; Randal S Weber; Gregory T Wolf; Frank Worden; Sue S Yom; Nicole McMillian; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-07 Impact factor: 11.908
Authors: Matthias Uhl; Thomas Welzel; Alexandra Jensen; Malte Ellerbrock; Thomas Haberer; Oliver Jäkel; Klaus Herfarth; Jürgen Debus Journal: Strahlenther Onkol Date: 2015-03-04 Impact factor: 3.621
Authors: Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy Journal: Front Oncol Date: 2022-06-14 Impact factor: 5.738
Authors: Robert M Samstein; Richard D Carvajal; Michael A Postow; Margaret K Callahan; Alexander N Shoushtari; Snehal G Patel; Nancy Y Lee; Christopher A Barker Journal: Head Neck Date: 2016-04-04 Impact factor: 3.147
Authors: Beata Sas-Korczynska; Marian Reinfuss; Jerzy W Mitus; Elzbieta Pluta; Anna Patla; Tomasz Walasek Journal: Rep Pract Oncol Radiother Date: 2018-08-17